You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Clinical trial of Moderna's coronavirus variant vaccine begins in US

A new Phase 1 clinical trial has started in the US to evaluate Moderna's investigational vaccine which is designed to protect against the B.1.351 coronavirus variant

Topics
Coronavirus Vaccine | US

IANS  |  Washington 

moderna, covid, vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Moderna's Covid-19 vaccine shots

A new Phase 1 clinical trial has started in the to evaluate Moderna's investigational vaccine which is designed to protect against the B.1.351 variant, the National Institutes of Health (NIH) announced.

The trial, led and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, will evaluate the safety and immunogenicity of the vaccine, known as mRNA-1273.351, in adult volunteers, Xinhua news agency quoted the announcement as saying on Wednesday.

The trial will enrol approximately 210 healthy adult volunteers at four clinical research sites in the US, according to the NIH.

"The B.1.351 SARS-CoV-2 variant, first identified in South Africa, has been detected in at least nine states in the US," NIAID Director Anthony Fauci was quoted as saying.

"Preliminary data show that the Covid-19 vaccines currently available in the should provide an adequate degree of protection against SARS-CoV-2 variants.

"However, out of an abundance of caution, NIAID has continued its partnership with Moderna to evaluate this variant vaccine candidate should there be a need for an updated vaccine," the top infectious diseases expert added.

The variant vaccine candidate differs from the currently-authorised Moderna jab in that it delivers instructions for making the SARS-CoV-2 spike that incorporates key mutations in the B.1.351 virus variant, according to the NIH.

In addition to the Phase 1 clinical trial, investigators at NIAID's Vaccine Research Center are collaborating with Moderna to evaluate mRNA-1273.351 in animal models.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 01 2021. 09:35 IST
RECOMMENDED FOR YOU